A Phase 3, Multi-center, Open-label Study To Investigate Safety, Efficacy, And Tolerability Of Sildenafil Citrate In Pediatric Patients With Pulmonary Arterial Hypertension

Trial Profile

A Phase 3, Multi-center, Open-label Study To Investigate Safety, Efficacy, And Tolerability Of Sildenafil Citrate In Pediatric Patients With Pulmonary Arterial Hypertension

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Sildenafil (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 23 Feb 2018 Planned End Date changed from 10 Apr 2018 to 1 Mar 2018.
    • 10 Jan 2018 Planned End Date changed from 30 Dec 2017 to 10 Apr 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top